Top entities: CEL-SCI Corporation, Multikine, ThinkEquity, United States — United States Securities and Exchange Commission.

What category does this event fall under?

Business — classified as public offering.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

CEL-SCI Corporation closed public offering · ThinkEquity acted as agent CEL-SCI Corporation · United States — United States Securities and Exchange Commission made effective CEL-SCI Corporation

Is this event still developing?

This is an active story, last updated May 13, 2026. Coverage continues to evolve.

Business public offering

CEL-SCI Closes Public Offering

Q: When did this event occur?

First reported May 12, 2026; last updated May 13, 2026.

Q: What is the market impact?

Direct. The public offering by CEL-SCI Corporation provides capital for the continued development of Multikine, which could positively impact the company's stock price and future prospects.

Analysis based on 6 articles · First reported May 12, 2026 · Last updated May 13, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The public offering by CEL-SCI Corporation provides capital for the continued development of Multikine, which could positively impact the company's stock price and future prospects. This event is directly relevant to investors in CEL-SCI Corporation and the biotechnology sector.

Biotechnology Pharmaceuticals

Event Summary

CEL-SCI Corporation, a clinical-stage cancer immunotherapy company, announced the closing of its best-efforts public offering of 6,000,000 shares of common stock at $1.20 per share, generating approximately $7.2 million in gross proceeds. The company intends to use these funds for the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity served as the sole placement agent for the offering. A registration statement for the shares was filed with the United States — United States Securities and Exchange Commission and became effective on May 11, 2026.

Key Actions

100 CEL-SCI Corporation closed public offering

50 ThinkEquity acted as agent CEL-SCI Corporation

20 United States — United States Securities and Exchange Commission made effective CEL-SCI Corporation

Entities Involved

stock

CEL-SCI Corporation

CEL-SCI Corporation closed a public offering of 6,000,000 shares of its common stock, raising approximately $7.2 million in gross proceeds to fund the continued development of Multikine, general corporate purposes, and working capital.

Importance 100 Sentiment 10

oth

Multikine

The proceeds from CEL-SCI Corporation's offering will be used for the continued development of Multikine, an investigational cancer immunotherapy.

Importance 70 Sentiment 0

priv

ThinkEquity

ThinkEquity acted as the sole placement agent for CEL-SCI Corporation's public offering.

Importance 50 Sentiment 0

govactor

United States — United States Securities and Exchange Commission

A registration statement for CEL-SCI Corporation's offering was filed with the United States — United States Securities and Exchange Commission and became effective on May 11, 2026.

Importance 20 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard